

Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF

JUSTIN L. GRODIN, MD, MPH,^{1,*} MAX J. LIEBO, MD,^{2,*} JAVED BUTLER, MD,³ MARCO METRA, MD,⁴ G. MICHAEL FELKER, MD,⁵ ADRIAN F. HERNANDEZ,⁵ ADRIAAN A. VOORS, MD,⁶ JOHN J. MCMURRAY, MD,⁷ PAUL W. ARMSTRONG, MD,⁸ CHRISTOPHER O'CONNOR, MD,⁹ RANDALL C. STARLING, MD, MPH,¹⁰ RICHARD W. TROUGHTON, MD, PhD,¹¹ AND W.H. WILSON TANG, MD⁹

Dallas, Texas; Maywood, Illinois; Jackson, Mississippi; Brescia, Italy; Durham, North Carolina; Groningen, The Netherlands; Glasgow, United Kingdom; Edmonton, Canada; Falls Church, Virginia; Cleveland, Ohio; and Christchurch, New Zealand

ABSTRACT

Background: Amino-terminal pro-B-type natriuretic peptide (NTproBNP) is closely associated with prognosis in acute decompensated heart failure (ADHF). As a result, there has been great interest measuring it during the course of treatment. The prognostic implications in both short-term and follow-up changes in NTproBNP need further clarification.

Methods: Baseline, 48–72 hour, and 30-day NTproBNP levels were measured in 795 subjects in the ASCEND-HF trial. Multivariable logistic and Cox-proportional hazards models were used to test the association between static, relative, and absolute changes in NTproBNP with outcomes during and after ADHF.

Results: The median NTproBNP at baseline was 5773 (2981–11,579) pg/mL; at 48–72 hours was 3036 (1191–6479) pg/mL; and at 30 days was 2914 (1364–6667) pg/mL. Absolute changes in NTproBNP by 48–72 hours were not associated with 30-day heart failure rehospitalization or mortality ($P = .065$), relative changes in NTproBNP were nominally associated ($P = .046$). In contrast, both absolute and relative changes in NTproBNP from baseline to 48–72 hours and to 30 days were closely associated with 180-day mortality ($P < .02$ for all) with increased discrimination compared to the multivariable models with baseline NTproBNP ($P < .05$ for models with relative and absolute change at both time points).

Conclusions: Although the degree of absolute change in NTproBNP was dependent on baseline levels, both short-term absolute and relative changes in NTproBNP were independently and incrementally associated with long-term clinical outcomes. Changes in NTproBNP levels at 30-days were particularly well associated with long-term clinical outcomes. (*J Cardiac Fail* 2019;25:703–711)

Key Words: Natriuretic peptide, nesiritide, acute heart failure.

The majority of the morbidity, mortality, and socioeconomic cost of heart failure (HF) is attributable to hospitalizations for acute decompensated heart failure (ADHF) and poor post-discharge outcomes.^{1–3} A number of time- and resource-intensive interventions have been shown to

improve outcomes in those at highest risk for subsequent events^{4–6}; however, identifying risk in this heterogeneous population remains a challenge. Natriuretic peptides, namely B-type natriuretic peptide and its amino-terminal cleavage equivalent (NTproBNP), have a wealth of

From the ¹Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; ²Department of Cardiology, Loyola University Medical Center, Maywood, Illinois; ³Department of Medicine, University of Mississippi, Jackson, Mississippi; ⁴Department of Cardiology, University of Brescia, Brescia, Italy; ⁵Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina; ⁶Hanzeplein 1, University Med Center Groningen, Groningen, The Netherlands; ⁷University of Glasgow, Glasgow, United Kingdom; ⁸Department of Cardiology, University of Alberta, Edmonton, Canada; Inova Heart and Vascular Institute; ⁹Heart and Vascular Institute, Falls Church, Virginia; ¹⁰Cleveland Clinic, Cleveland, Ohio and ¹¹University of Otago, Christchurch, New Zealand.

Manuscript received September 9, 2018; revised manuscript received March 25, 2019; revised manuscript accepted April 2, 2019.

Reprint requests: W.H. Wilson Tang, MD, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH 44195. E-mail: tangw@ccf.org

Funding: The ASCEND-HF study, including the biomarker substudy, was funded by Scios Inc; Janssen Research & Development LLC retains operational responsibility for the ASCEND-HF study. Ortho Clinical Diagnostics performed all NTproBNP assays, and was blinded from the trial database or analyses. Statistical analyses, and manuscript preparation were conducted independent of the sponsors, and the authors have access to all the data in its entirety and approved the final manuscript.

See page 710 for disclosure information.

*J.L.G. and M.J.L. contributed equally to this work.

1071-9164/\$ - see front matter

© 2019 Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.cardfail.2019.04.002>

evidence supporting their use as powerful noninvasive prognostic markers when measured at baseline or during the course of treatment for ADHF.^{7–14} As a result, changes in NTproBNP levels are commonly used to monitor clinical improvement and are used as endpoints in ADHF clinical trials.^{15,16} However, more clarity is needed regarding 3 important key topics pertaining to NTproBNP change: the dependency of absolute or relative NTproBNP change on baseline levels¹; the prognostic impact of absolute or relative NTproBNP change²; and whether baseline NTproBNP levels influence the risk associated with NTproBNP change.³

To address these questions, we analyzed data from a pre-specified biomarker substudy of Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) using a clinically available assay for NTproBNP.¹⁷

Methods

Study Population

The ASCEND-HF trial was a multicenter, randomized, double-blind placebo-controlled trial that sought to determine the effects of nesiritide, a recombinant B-type natriuretic peptide with vasodilating properties, in patients hospitalized with ADHF. Participants with clinical evidence for an acute coronary syndrome or baseline cardiac troponin >5x the upper reference limit, as measured by the local clinical laboratory, were excluded. The design and primary results of ASCEND-HF were previously reported.^{17,18} Of the 7411 patients randomized, 904 were enrolled into a pre-specified biomarker substudy. These patients had serial venous blood sampling at baseline, 48–72 hours after therapy initiation, and at a 30-day follow-up visit.^{19–22} Blood samples were collected in ethylenediaminetetraacetic acid–plasma, immediately centrifuged and stored at –80°F for analysis at a core laboratory blinded to all clinical data.

NTproBNP Measurement

Circulating NTproBNP levels were determined with a clinically available NTproBNP assay (VITROS NTproBNP, Ortho Clinical Diagnostics, Raritan, NJ). Briefly, the linear range of the assay is 2.29 to 44,700 pg/mL with a limit of detection calculated at 4.29 pg/mL and a 20% coefficient of variation at 9.4 pg/mL.²³

Clinical Endpoints

The co-primary endpoints from the ASCEND-HF trial were dyspnea improvement (via 7-point Likert scale) at 6 to 24 hours and the composite endpoint of death or recurrent HF hospitalization within 30 days of randomization. Death and worsening HF were assessed together as a composite secondary endpoint and all events were adjudicated through 180 days.

Statistical Analyses

Absolute change in NTproBNP from baseline to 48–72 hours was calculated as: 48–72 hour NTproBNP – baseline NTproBNP. Relative change in NTproBNP from baseline to 48–72 hours was calculated as: $100 \times (48-72 \text{ hour NTproBNP} - \text{baseline NTproBNP}) / (\text{baseline NTproBNP})$. The same method was used to determine absolute and relative changes in NTproBNP from baseline to 30 days. Baseline characteristics were presented as median (interquartile range) for continuous variables and as percentage for categorical variables. Right-skewed variables were transformed via log-base-2 to represent the doubling of the variable values. Variables were transformed as linear splines where appropriate. Scatterplots were generated to show the relationship between static and changes in NTproBNP levels. The Jonckheere–Terpstra and Cochran–Armitage trend tests were used to test trend across tertiles of absolute change in NTproBNP and relative change in NTproBNP from baseline to 48–72 hours for continuous and categorical variables, respectively. Spearman correlation coefficients were generated to determine correlates between both static and changes in NTproBNP levels. The Kaplan–Meier method was used to plot cumulative 180-day mortality stratified by tertiles of absolute and relative change in NTproBNP and differences in curves were compared via the log rank test. The associations of the static and changes in NTproBNP levels and 30-day clinical outcomes and 180-day mortality were performed via logistic regression and Cox-proportional hazards models, respectively. The proportional hazards assumption was verified by determining whether there were trends with time for the Schoenfeld residuals. For multivariable analyses, we adjusted for covariates identified for the overall ASCEND-HF study population, which were previously described (Supplement 1).^{19–22} All models incorporating either absolute or relative changes in NTproBNP were additionally adjusted for the static baseline NTproBNP level and were landmark analyses from the time of the follow-up measurement. Harrell's concordance statistics (C-statistic) were determined to describe the additive discrimination impact of static or changes in NTproBNP levels on 180-day mortality to the ASCEND-HF models.²⁴ Continuous by continuous interactions to determine the prognostic effect of NTproBNP level changes given baseline NTproBNP levels were also tested. Margins plots were generated to display the continuous relationship between changes in NTproBNP levels across a spectrum of baseline levels. Mixed-effects models with unstructured variance tested the association between study treatment assignment and serial NTproBNP levels. Two-sided *P* values < .05 were considered statistically significant. All statistical analyses were performed using Stata software, version 13.1 (StataCorp LP, College Station, TX).

Results

Study Population

Of the 795 patients with baseline NTproBNP levels (Supplement 2), 746 had NTproBNP levels drawn at 48–72 hours, and 659 had NTproBNP levels drawn at 30 days. The median




Fig. 1. Scatterplots of 48–72 hour changes in NTproBNP Levels by baseline NTproBNP levels. The plots represent both (a) absolute change and (b) relative change. The horizontal axes on a log-base-2 transformed scale.

NTproBNP at baseline was 5773 (2981–11,579) pg/mL; at 48–72 hours was 3036 (1191–6479) pg/mL; and at 30 days was 2914 (1364–6667) pg/mL. Figure 1a and 1b illustrates the relationship between baseline NTproBNP levels and either absolute and relative change in NTproBNP from baseline to 48–72 hours, respectively. Figure 1a qualitatively highlights the dependency of the magnitude of absolute NTproBNP changes on the baseline NTproBNP level. This is in contrast to Figure 1b, which suggests no such dependency between relative changes in NTproBNP on the baseline NTproBNP level.

Baseline characteristics across increasing tertiles in magnitude of absolute NTproBNP change from baseline to 48–72 hours are shown in Table 1. Increasing tertiles in

magnitude of absolute NTproBNP change (more NTproBNP decrease) were associated with older age, less prevalent male sex and diabetes; but were not associated with race, ischemic HF, or ejection fraction. Although increasing magnitude of absolute NTproBNP change was significantly associated with higher sodium and cystatin C levels, the trend in these lower levels was only modest and there were no complimentary associations between increasing tertiles in magnitude of absolute NTproBNP change and other cardiorenal markers of neurohormonal activation such as BUN or creatinine.

This is in contrast to the baseline characteristics across increasing tertiles in magnitude of relative NTproBNP change from baseline to 48–72 hours, which are shown in Table 2.

Table 1. Baseline Characteristics Across Tertiles of Absolute Change in NTproBNP From Baseline to 48–72 hours

Characteristic	Absolute Change in NTproBNP [pg/mL]			P Trend
	> -1280 (N = 224)	-1280 to -3850 (N = 227)	< -3850 (N = 226)	
Age [y]	65 [52–77]	65 [54–76]	71 [59–80]	<.001
Male	172 (76.8)	173 (76.1)	136 (60.2)	<.001
White	149 (66.5)	153 (67.4)	163 (72.1)	.20
Black	68 (30.4)	70 (30.8)	53 (23.4)	.10
Diabetes	123 (54.9)	103 (45.4)	101 (44.7)	.03
Ischemic HF	140 (62.5)	129 (56.8)	148 (65.5)	.52
NYHA Class 3 or 4	117 (69.6)	118 (73.3)	114 (72.2)	.61
Elevated JVP	152 (67.9)	151 (66.5)	133 (58.9)	.046
BMI [kg/m ²]	31.7 [26.3–39.4]	31.1 [26.7–36.6]	28.0 [24.4–32.7]	<.001
Heart rate [bpm]	77 [68–88]	80 [70–92]	77 [70–86]	.95
SBP [mm Hg]	120 [108–135]	128 [114–141]	128 [114–142]	<.001
Ejection fraction [%]	30 [18–40]	26 [20–40]	25 [20–40]	.91
Albumin [g/dL]	3.5 [3.2–4.0]	3.6 [3.3–3.9]	3.5 [3.2–3.9]	0.64
ALT [U/L]	26 [17–38]	29 [19–42]	25 [16–46]	.049
AST [U/L]	27 [21–39]	28 [20–41]	26 [21–37]	.63
Total bilirubin [μ mol/L]	15.4 [10.1–25.7]	15.4 [10.3–20.5]	13.7 [9.0–20.5]	.12
Sodium [mmol/L]	138 [135–141]	140 [137–141]	139 [137–141]	.002
BUN [mg/dL]	24 [17–40]	21 [16–31]	28 [21–37]	.051
Creatinine [mg/dL]	1.3 [1.1–1.8]	1.2 [1.0–1.5]	1.4 [1.1–1.9]	.11
Cystatin C [g/dL]	1.5 [1.2–2.1]	1.4 [1.1–1.7]	1.7 [1.3–2.1]	.005
Troponin I [pg/mL]	13.5 [7.9–26.5]	15.6 [8.5–31.5]	20.2 [12.6–43.0]	<.001
NTproBNP [pg/mL]	2,898 [1405–6334]	4,354 [3037–6296]	13,653 [9631–22,427]	<.001
sST2 [ng/mL]	65.8 [44.0–100.4]	69.2 [49.2–103.5]	93.9 [63.9–134.8]	<.001
Beta-blocker	160 (71.4)	176 (77.5)	182 (80.5)	.023
MRA	60 (26.8)	55 (24.2)	48 (21.2)	.17
RAS-blocker	143 (63.8)	150 (66.1)	136 (60.2)	.42

NYHA, New York Heart Association; JVP, jugular venous pressure; BMI, body mass index; SBP, systolic blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; NTproBNP, N-terminal pro–B-type natriuretic peptide; sST2, soluble ST2; MRA, mineralocorticoid antagonist; and RAS, renin-angiotensin system.

Table 2. Baseline Characteristics Across Tertiles of Relative Change in NTproBNP from Baseline to 48–72 hours

Characteristic	Relative Change in NTproBNP [%]			P Value
	> -30 (N = 225)	-30 to -61 (N = 226)	< -61 (N = 226)	
Age [y]	68 (56–79)	67 (56–78)	64 (54–77)	.12
Male	174 (77.3)	164 (72.6)	143 (63.3)	.001
White	153 (68.0)	165 (73.0)	147 (65.0)	.50
Black	60 (26.7)	57 (25.2)	74 (32.7)	.15
Diabetes	124 (55.1)	99 (43.8)	104 (46.0)	.054
Ischemic Heart Failure	159 (70.7)	136 (60.2)	122 (54.0)	<.001
NYHA Class 3 or 4	125 (71.8)	116 (78.4)	108 (68.4)	.50
Elevated JVP	161 (71.6)	139 (61.5)	136 (60.2)	.01
BMI [kg/m ²]	29.6 (25.0–36.0)	29.7 (25.3–35.4)	31.0 (26.3–37.1)	.14
Heart rate [bpm]	77 (68–87)	79 (69–88)	80 (70–90)	.09
SBP [mm Hg]	119 (108–133)	126 (113–139)	131 (116–145)	<.001
Ejection Fraction [%]	25 (18–35)	25 (20–40)	30 (20–45)	.009
Albumin [g/dL]	3.5 (3.1–3.9)	3.6 (3.2–3.9)	3.6 (3.3–4.0)	.06
ALT [U/L]	24 (17–36)	25 (17–40)	26 (17–46)	.13
AST [U/L]	28 (21–37)	28 (21–40)	25 (20–35)	.13
Total Bilirubin [μ mol/L]	17.1 (11.0–25.8)	15.4 (10.3–20.5)	13.3 (8.6–20.5)	.001
Sodium [mmol/L]	139 (135–141)	139 (136–141)	140 (138–141)	.002
BUN [mg/dL]	29 (21–44)	24 (18–34)	22 (16–30)	<.001
Creatinine [mg/dL]	1.4 (1.2–2.0)	1.3 (1.0–1.7)	1.2 (1.0–1.5)	<.001
Cystatin C [g/dL]	1.6 (1.3–2.5)	1.5 (1.2–1.9)	1.4 (1.2–1.8)	<.001
Troponin I [pg/mL]	17.7 (10.2–32.0)	14.3 (8.5–29.7)	17.6 (9.8–35.1)	.79
NTproBNP [pg/mL]	6,018 (2982–12,084)	6,037 (3029–12,936)	5,693 (3032–11,294)	.68
sST2 [ng/mL]	80.4 (52.0–116.0)	73.2 (48.8–118.5)	71.5 (49.4–110.8)	.51
Beta-Blocker	169 (75.1)	180 (80.0)	169 (74.8)	.93
MRA	61 (27.1)	58 (25.7)	44 (19.5)	.06
RAS-Blocker	135 (60.0)	147 (65.0)	147 (65.0)	.27

NYHA, New York Heart Association; JVP, jugular venous pressure; BMI, body mass index; SBP, systolic blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; NTproBNP, N-terminal pro–B-type natriuretic peptide; sST2, soluble ST2; MRA, mineralocorticoid antagonist; and RAS, renin-angiotensin system.

These highlight the differential relationships between the type of NTproBNP change and demographics and clinical characteristics. Increasing tertiles in magnitude of relative NTproBNP change (more relative NTproBNP decrease) were not associated with age or diabetes, but were closely associated with less prevalent male sex and ischemic HF. Relative NTproBNP change from baseline to 48–72 hours was more closely associated with classic clinical markers of HF severity including ejection fraction, total bilirubin and cardiorenal neurohormonal activation: sodium, BUN, creatinine, and cystatin C.

Along similar lines to the relationships in Figures 1a and 1b, absolute changes in NTproBNP from baseline to 48–72 hours were closely related to baseline levels of commonly used prognostic biomarkers in HF: cardiac troponin I, NTproBNP, and sST2 (Table 1). On the other hand, relative changes in NTproBNP from baseline to 48–72 hours were not associated with these biomarkers (Table 2).

Correlation Between Static and Changes in NTproBNP Levels

Spearman correlation coefficients were generated to determine the monotonic relationships between the static NTproBNP levels measured at baseline, 48–72 hours, and 30 days to both absolute and relative changes between baseline NTproBNP levels at the 2 follow-up time points and are shown in Table 3. Static NTproBNP levels at all 3 time points were all highly correlated. However, there was a contrasting relationship between baseline and follow-up NTproBNP levels according to the type of change. Absolute changes in NTproBNP were modestly correlated with their baseline levels, where relative changes in NTproBNP were modestly correlated with their follow-up levels.

Changes in NTproBNP and Clinical Outcomes

There were $n/N = 95/782$ and $83/667$ HF hospitalizations or deaths by 30 days from baseline and 48–72 hours, respectively. Logistic regression models with adjusted odds ratios are shown in Table 4. Baseline NTproBNP was not associated with 30-day HF hospitalization or death ($P = .18$). However, follow-up NTproBNP measured at 48–72 hours was significantly associated with 30-day HF hospitalization or death ($P = .013$), and is likely more closely representative of relative NTproBNP change ($P = .046$) compared with absolute NTproBNP change ($P = .065$). There was no improvement in discrimination when either the static or changes by 48–72 hours in NTproBNP were added to the ASCEND-HF model (Table 4; $P > .05$ for all).

There were $n/N = 96/795$, $82/746$, and $52/659$ deaths by 180 days from baseline, 48–72 hours, and 30 days, respectively. For patients with available NTproBNP change data, there were $n/N = 78/677$ and $46/582$ deaths by 180 days for 48–72 hour and 30 days, respectively. Kaplan–Meier estimates of cumulative mortality are shown in Figure 2a and 2b for tertiles of NTproBNP absolute change and relative change in levels from baseline to 48–72 hours, respectively.

Table 3. Spearman Correlates Between Static and Changes in NTproBNP Levels*

	Baseline NT proBNP [†]	48–72 Hour NTproBNP [†]	30 Day NT proBNP [†]	Absolute Δ in NTproBNP to 48–72 Hours	Absolute Δ in NT proBNP to 30 Days	Relative Δ in NTproBNP to 48–72 Hours	Relative Δ in NTproBNP to 30 Days
Baseline NTproBNP [†]	—						
48–72 hour NTproBNP [†]	0.82	—		–0.68	–0.62	0.02**	–0.19
30 day NTproBNP [†]	0.71	0.77	—	–0.25	–0.35	0.54	0.08**
Absolute Δ in NTproBNP to 48–72 hours	–0.68	0.77	–	–0.30	–0.02**	0.30	0.49
Absolute Δ in NTproBNP to 30 days	–0.62	–0.25	–0.30	—	0.68	0.59	0.41
Relative Δ in NTproBNP to 48–72 hours	0.02**	0.54	–0.02**	0.68	—	0.28	0.78
Relative Δ in NTproBNP to 30 days	–0.19	0.08**	0.49	0.59	0.28	—	0.44
				0.41	0.78	0.44	—

*Units of NTproBNP and absolute Δ in NTproBNP are pg/mL and Relative Δ in NTproBNP is percentage.

** $P > .05$ otherwise all $P < .001$.

[†]log-base-2 transformed.

Table 4. Association of Static NTproBNP and Changes in NTproBNP Levels and 30- and 180-Day Clinical Outcomes Added to the ASCEND-HF Model

Variable	Outcome	HR/OR [†]	95% CI for HR/OR	P Value	C-Statistic*	95% CI for C-Statistic
Baseline NTproBNP	30-day HF hosp. or mortality	1.13	0.94–1.36	.184	0.72	0.66–0.77
	180-day mortality	1.37	1.17–1.60	<.001	0.74	0.69–0.79
48–72 hour NTproBNP	30-day HF hosp. or mortality	1.23	1.04–1.44	.013	0.73	0.68–0.79
	180-day mortality	1.50	1.29–1.74	<.001	0.76 ^{‡,§}	0.71–0.82
Abs. Δ in NTproBNP to 48–72 hours	30-Day HF hosp. or mortality	1.02	0.99–1.02	.065	0.73	0.68–0.79
	180-day mortality	1.02	1.003–1.03	.014	0.76 ^{‡,§}	0.70–0.81
% Δ in NTproBNP to 48–72 hours	30-day HF hosp. or mortality	1.12	1.002–1.25	.046	0.73	0.68–0.78
	180-day mortality	1.15	1.04–1.27	.005	0.75 [‡]	0.70–0.81
30 day NTproBNP	180-day mortality	1.76	1.43–2.16	<.001	0.78 ^{‡,§}	0.71–0.84
Abs. Δ in NTproBNP to 30 days	180-day mortality	1.02	1.01–1.03	.003	0.77 ^{‡,§}	0.70–0.84
% Δ in NTproBNP to 30 days	180-day mortality	1.18	1.09–1.27	<.001	0.77 ^{‡,§}	0.70–0.84

HR, hazard ratio; OR, odds ratio; hosp., hospitalization; abs, absolute.

*C-Statistics represent the discrimination of the exposures of interest (static NTproBNP or Δ NTproBNP) with variables from the ASCEND-HF model for 30-day HF hosp. or mortality and 180-day mortality. C-statistics for the variables in the baseline ASCEND-HF model are 0.71 (95% CI 0.66–0.77) and 0.71 (95% CI 0.66–0.77) for 30-day HF hosp. and 180-day mortality, respectively.

[†]For static NTproBNP, HR/OR represent every log-base-2 change; for Abs. Δ in NTproBNP, HR represent per 500 pg/mL change; and for % Δ in NTproBNP, HR represent per 20% change. All point estimates are multivariable adjusted for baseline variables in the ASCEND-HF model.

[‡]For C-statistic comparison to baseline ASCEND-HF model $P < .05$.

[§]For C-statistic comparison to the model with baseline ASCEND-HF variables and NTproBNP levels, $P < .05$.

^{||}P value for HR/OR.

Cox-proportional hazards models with the adjusted hazards ratios are shown in Table 4. Not surprisingly, all static NTproBNP levels measured at each of the three time points were significantly associated with 180-day mortality risk. Every doubling in static NTproBNP levels had an approximate 37%, 50%, and 76% increased risk of 180-day mortality for NTproBNP checked at baseline, 48–72 hours, and 30 days; respectively. Both absolute and relative change in NTproBNP from baseline to 48–72 hours and from baseline to 30 days were significantly associated with 180-day mortality. An absolute 500 pg/mL increase in NTproBNP from baseline to either follow-up time point was associated with an approximate 2% increased risk of 180-day mortality. A relative 20% increase in NTproBNP from baseline to 48–72 hours and from baseline to 30 days was associated with a significant 15% and 18% increased risk in 180-day mortality, respectively. With the exception of baseline NTproBNP, which showed a trend toward improved discrimination versus the baseline ASCEND-HF model ($C = 0.74$ vs $C = 0.71$, respectively, $P = .06$) for 180-day mortality; all models with follow-up static NTproBNP levels or changes in NTproBNP had improved discrimination than the baseline ASCEND-HF model ($P < .05$ for all).

First-order and second-order Interactions were tested between baseline NTproBNP levels and both types of NTproBNP changes to each time point and were nonsignificant ($P > .05$ for all). Therefore, despite the differential dependency of absolute or relative NTproBNP change on either baseline or follow-up levels, the risk attributed to NTproBNP change was statistically associated with the baseline level. The graphical risk-relationship between absolute and relative changes according to various baseline NTproBNP levels is shown in Supplement 3. Although the modelled risk-relationship for different levels of absolute change and relative change in NTproBNP

differed in shape (linear vs curvilinear, respectively), both show relatively parallel increments or decrements in risk attributable to NTproBNP change given baseline NTproBNP levels.

Discussion

This analysis from the ASCEND-HF biomarker substudy highlights important concepts adding to our understanding of changes in NTproBNP in patients with ADHF. The primary finding was that both absolute and relative changes in NTproBNP were highly independently and incrementally prognostic to static baseline NTproBNP levels. Furthermore, although absolute NTproBNP changes from baseline were highly dependent on baseline NTproBNP levels, baseline NTproBNP levels had no impact on either NTproBNP change (absolute or relative) risk-relationship. These findings underscore what has become a solid body of evidence supporting the prognostic value of natriuretic peptides in HF and enlighten the interpretation of natriuretic peptide changes during ADHF.

Since their association with HF was first described,²⁵ B-type natriuretic peptide (BNP, and its biologically inert split-product NTproBNP) have been of great interest for their clinical use in managing HF²⁶ and in clinical research where their values inform patient selection and yield important mechanistic insights to therapeutic responses. Serum natriuretic peptide levels fluctuate in parallel with intracardiac hemodynamics during both decompensation and clinical improvement.^{27–30} Not surprisingly, these fluctuations during the treatment of ADHF also prognosticate the likelihood of rehospitalization and death after discharge.^{7–14,31,32} Therefore, our finding that static NTproBNP is associated with both 30- and 180-day adverse clinical outcomes underscores the clinical importance of this biomarker and continues to emphasize its prognostic role in ADHF.




Fig. 2. Kaplan–Meier estimates of 180-day mortality across 48–72 hour changes in NTproBNP levels. The plots represent tertiles of (a) absolute change and (b) relative change.

When checked at different time points during the course of treatment for ADHF, natriuretic peptide measurements might confer different prognostic information. In particular, both BNP and NTproBNP levels measured at hospital discharge are likely more reflective of both HF rehospitalization and mortality.^{8,10–12,14,33} Reasons for this are perhaps reflective of the achievement of a more stable hemodynamic and cardiorenal state following treatment for ADHF. Our finding that both types of NTproBNP change whether in the short-term (48–72 hours) or mid-term (30 days) were independently and incrementally prognostic to their static baseline counterparts (in addition to factors derived by the ASCEND-HF model) supports prior these findings. However, they also suggest that changes in NTproBNP levels when checked early, during the course of treatment for ADHF, stratify risk (likely representing

treatment response), and identify long-term prognosis, thus obviating the need to check discharge NTproBNP.

Indeed, prior cohorts have placed emphasis on the relative reduction in NTproBNP from baseline to discharge and its impact on HF readmission^{9,13,31,34}; and, not surprisingly, relative changes have been considered as surrogate endpoints for treatment efficacy in ADHF.¹⁵ The distinction between absolute and relative changes extends beyond mathematical concepts. As shown in Table 2 and Figure 1a absolute changes in NTproBNP may be dependent on their baseline levels, whereas relative changes in NTproBNP may be dependent on their follow-up levels and therefore likely more reflective of treatment. Given their different associations with baseline clinical and metabolic characteristics, the degree of relative changes in NTproBNP is likely

more reflective of the degree of cardiorenal neurohormonal activation at baseline (ie, serum sodium, BUN, and creatinine/cystatin C, well-known parameters associated treatment response)³⁵ not captured by the baseline NTproBNP levels alone.

A prior compilation of seven ADHF cohorts has also emphasized the differences between absolute and relative targets in NTproBNP levels from baseline to discharge.³² Thematically similar to our findings, they found that absolute and relative NTproBNP targets predischARGE were prognostic and that relative NTproBNP targets offered more consistent prognostic information. However, our analysis adds a more robust understanding of NTproBNP changes in 3 ways: 1) there is valuable prognostic information in short-term absolute or relative changes in NTproBNP; 2) although independent of, the prognostic modification of risk is related to the baseline NTproBNP risk-relationship for both absolute and relative changes; but 3) the trajectory of risk was not modified by baseline NTproBNP levels. It is also worth noting, that short-term changes in NTproBNP might be more reflective of risk for long-term outcomes compared with shorter-term clinical outcomes such as 30-day HF readmissions.

The results of this study must be interpreted in light of various limitations inherent to its design. First, we cannot exclude selection bias for patients whom agreed to participate in the ASCEND-HF trial. Although, the baseline characteristics of this cohort (Table 1) are representative of contemporary ADHF populations. Second, there was a paucity of data to assess the contribution of other HF pharmacotherapies to changes in NTproBNP levels during treatment that might have a deferential impact on clinical events. Worth noting however, there was no association with those randomized to nesiritide and serial NTproBNP levels (Supplement 4) and it did not modify the risk-relationship of NTproBNP on 30- and 180-day clinical outcomes (*P* interaction > .1 for both, respectively). Regardless, our analysis suggests that both absolute and relative changes in NTproBNP are prognostically informative and provides insight into early and follow-up natriuretic peptide measurements in HF.

Conclusions

Although the degree of absolute change in NTproBNP was dependent on baseline levels, both short-term absolute and relative changes in NTproBNP were independently and incrementally associated with long-term clinical outcomes. NTproBNP levels at follow-up were particularly well associated with long-term clinical outcomes. These findings support the hypothesis that short-term changes in NTproBNP, soon after the initiation of therapy and before discharge, can identify patients with high-risk ADHF.

Disclosure

J. Grodin: None. M. Liebo: None. J. Butler: Consultant/Advisory Board; Modest; Johnson&Johnson. M. Metra: Consultant/Advisory Board; Modest; Corthera, Daiichi, Novartis, Serrvier. G. Felker: Research Grant; Significant; Johnson&Johnson, Roche Diagnostics, Critical Diagnostics, BG Medicine. A. A.

Voors: Consultant/Advisory Board; Modest; Johnson&Johnson, Alere, Bayer, Boehringer Ingelheim, Cardio3Biosciences, Celadon, Merck/MSD, Novartis, Servier, Trevena, Vifor Pharma. J. J. McMurray: Research Grant; Significant; Johnson&Johnson. P. W. Armstrong: Research Grant; Significant; Johnson&Johnson, Ortho Biotech. A. F. Hernandez: Research Grant; Significant; Johnson&Johnson. C. M. O'Connor: Research Grant; Significant; Johnson&Johnson. R. C. Starling: Other Research Support; Modest; Johnson&Johnson. Consultant/Advisory Board; Modest; Johnson&Johnson. W. Tang: MyoKardia Inc, Sequanal Medical Inc.

Supplementary materials

Supplementary material associated with this article can be found in the online version at [doi:10.1016/j.cardfail.2019.04.002](https://doi.org/10.1016/j.cardfail.2019.04.002).

References

1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: a Report From the American Heart Association. *Circulation* 2017;135:e146–603.
2. Gheorghade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. *J Am Coll Cardiol* 2013;61:391–403.
3. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. *JAMA* 2011;306:1669–78.
4. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. *N Engl J Med* 1995;333:1190–5.
5. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. *J Am Coll Cardiol* 2004;44:810–9.
6. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. *JAMA* 2010;303:1716–22.
7. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. *J Am Coll Cardiol* 2001;37:386–91.
8. Bettencourt P, Ferreira S, Azevedo A, Ferreira A. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. *Am J Med* 2002;113:215–9.
9. Bettencourt P, Azevedo A, Pimenta J, Frieos F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. *Circulation* 2004;110:2168–74.
10. Logeart D, Thabut G, Jourdain P, et al. PredischARGE B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. *J Am Coll Cardiol* 2004;43:635–41.
11. Kociol RD, Horton JR, Fonarow GC, et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. *Circ Heart Fail* 2011;4:628–36.

12. Verdiani V, Nozzoli C, Bacci F, et al. Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. *Eur J Heart Fail* 2005;7:566–71.
13. Bayes-Genis A, Lopez L, Zapico E, et al. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. *J Card Fail* 2005;11:S3–8.
14. Waldo SW, Beede J, Isakson S, et al. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. *J Am Coll Cardiol* 2008;51:1874–82.
15. Butler J, Hernandez AF, Anstrom KJ, et al. Rationale and design of the ATHENA-HF Trial: aldosterone targeted neuro-hormonal combined with natriuresis therapy in heart failure. *JACC Heart Fail* 2016;4:726–35.
16. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. *J Am Coll Cardiol* 2013;61:196–206.
17. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. *N Engl J Med* 2011;365:32–43.
18. Hernandez AF, O'Connor CM, Starling RC, et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). *Am Heart J* 2009;157:271–7.
19. Felker GM, Hasselblad V, Tang WH, et al. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. *Eur J Heart Fail* 2012;14:1257–64.
20. Tang WH, Dupont M, Hernandez AF, et al. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. *JACC Heart Fail* 2015;3:40–9.
21. Grodin JL, Perez AL, Wu Y, et al. Circulating kidney injury molecule-1 levels in acute heart failure: insights from the ASCEND-HF Trial (acute study of clinical effectiveness of nesiritide in decompensated heart failure). *JACC Heart Fail* 2015;3:777–85.
22. Perez AL, Grodin JL, Wu Y, et al. Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. *Eur J Heart Fail* 2016;18:290–7.
23. Januzzi Jr JL, Lewandowski KB, Bashirians G, et al. Analytical and clinical performance of the Ortho-Clinical Diagnostics VITROS amino-terminal pro-B type natriuretic peptide assay. *Clin Chim Acta* 2008;387:48–54.
24. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med* 1996;15:361–87.
25. Mukoyama M, Nakao K, Saito Y, et al. Increased human brain natriuretic peptide in congestive heart failure. *N Engl J Med* 1990;323:757–8.
26. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2013;128:1810–52.
27. Knebel F, Schimke I, Pliet K, et al. NT-ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. *J Card Fail* 2005;11:S38–41.
28. Shah MR, Hasselblad V, Tasissa G, et al. Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). *Am J Cardiol* 2007;100:1427–33.
29. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. *J Card Fail* 2001;7:21–9.
30. Gackowski A, Isnard R, Golmard JL, et al. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. *Eur Heart J* 2004;25:1788–96.
31. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. *J Am Coll Cardiol* 2009;53:2343–8.
32. Stienen S, Salah K, Eurlings LW, et al. Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels? *Eur J Heart Fail* 2015;17:936–44.
33. Omar HR, Guglin M. Discharge BNP is a stronger predictor of 6-month mortality in acute heart failure compared with baseline BNP and admission-to-discharge percentage BNP reduction. *Int J Cardiol* 2016;221:1116–22.
34. Di Somma S, Marino R, Zampini G, et al. Predictive value for death and rehospitalization of 30-day postdischarge B-type natriuretic peptide (BNP) in elderly patients with heart failure: sub-analysis of Italian RED Study. *Clin Chem Lab Med* 2015;53:507–13.
35. Valente MA, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. *Eur Heart J* 2014;35:1284–93.